TD Cowen raised the firm’s price target on Ultragenyx (RARE) to $86 from $73 and keeps a Buy rating on the shares. The firm updated it mdoel following Q4 results as they believe the copmany made solid prgress during the quarter.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Pharmaceutical: Promising Growth Prospects with Strong Financial Outlook and Key Pipeline Developments
- Promising Developments in Ultragenyx Pharmaceuticals Drive Ed Arce’s Buy Rating
- Ultragenyx Pharmaceutical Reports Strong 2024 Growth
- Ultragenyx Pharmaceutical’s Strong Sales and Promising Pipeline Support Buy Rating
- Ultragenyx reports Q4 EPS ($1.39), consensus ($1.27)